Craig Mello

Craig Cameron Mello
Born	Craig Cameron Mello 10/18/1960
Birthplace	New Haven, Connecticut, U.S.
Nationality	American
Occupation	Biologist, professor
Title	Professor, RNA Therapeutics Institute and Program for Molecular Medicine
Employer	University of Massachusetts Chan Medical School
Known for	RNA interference
Education	Brown University (BS) Harvard University (PhD)
Awards	Nobel Prize in Physiology or Medicine (2006), Canada Gairdner International Award (2005), Wiley Prize (2003)

Craig Cameron Mello (born October 18, 1960) is an American biologist and professor at the University of Massachusetts Chan Medical School in Worcester, Massachusetts, where he holds positions in the RNA Therapeutics Institute and the Program for Molecular Medicine. In 2006, Mello and his collaborator Andrew Z. Fire were jointly awarded the Nobel Prize in Physiology or Medicine for their discovery of RNA interference (RNAi), a fundamental biological mechanism by which double-stranded RNA molecules can silence the expression of specific genes. Their landmark research, published in the journal Nature in 1998, demonstrated that the introduction of double-stranded RNA into the nematode Caenorhabditis elegans triggered a potent and specific gene-silencing response, a finding that transformed the understanding of gene regulation across biology. Since 2000, Mello has served as an investigator of the Howard Hughes Medical Institute. His discovery of RNAi has had profound implications for both basic science and medicine, laying the groundwork for an entire class of RNA-based therapeutics that began reaching clinical application in the late 2010s.

Early Life

Craig Cameron Mello was born on October 18, 1960, in New Haven, Connecticut. He grew up in a family that valued intellectual curiosity and scientific inquiry. His father, James Mello, was a paleontologist affiliated with the United States Geological Survey, and young Craig was exposed to the natural sciences from an early age. His upbringing in an environment where scientific exploration was part of everyday life helped cultivate his interest in understanding the mechanisms underlying biological processes.

As a child, Mello developed an early fascination with how living organisms work and how the natural world is organized. His father's work in paleontology provided him with an appreciation for the deep history of life on Earth, while his broader exposure to science sparked questions about the molecular foundations of biology. These formative experiences would later shape his decision to pursue a career in molecular biology and genetics.

Mello spent portions of his youth in the northern Virginia area, where his father was stationed for his work with the Geological Survey. The family's connection to scientific institutions and the academic world provided Mello with role models and opportunities that reinforced his growing interest in the biological sciences. In his Nobel biographical essay, Mello has reflected on how these early encounters with practicing scientists shaped his sense of what a scientific career could look like, and instilled in him the conviction that fundamental questions about life are worth pursuing with rigor and patience.

Education

Mello pursued his undergraduate education at Brown University in Providence, Rhode Island, where he earned a Bachelor of Science degree in biochemistry. At Brown, he studied under several faculty members who influenced his scientific development, including Nelson Fausto, Susan Gerbi, Ken Miller, and Frank Rothman. These mentors helped him build a strong foundation in molecular biology and genetics, and introduced him to the rigorous experimental approaches that would characterize his later research. The environment at Brown encouraged broad scientific thinking across disciplines, and Mello has credited his undergraduate education with giving him both the technical skills and the intellectual confidence to tackle difficult biological problems.

After completing his undergraduate studies, Mello enrolled at Harvard University for his doctoral work. At Harvard, he pursued research in developmental biology and genetics, earning his Ph.D. His graduate training provided him with expertise in the molecular genetics of model organisms, particularly in understanding how genes control developmental processes. His doctoral advisors included Victor Ambros and Daniel Stinchcomb, both of whom were influential in shaping his approach to studying gene regulation. Ambros, who would himself later win the Nobel Prize in Physiology or Medicine in 2024 for his co-discovery of microRNA, was a particularly important mentor and later became a colleague at the University of Massachusetts Chan Medical School.

The overlap of Mello's graduate training with Ambros's early research on developmental timing in C. elegans was formative. It was during this period that Mello became deeply familiar with the nematode worm as a model system, an acquaintance that would directly inform his later collaboration with Andrew Fire. The small RNA field that eventually united Mello's and Ambros's separate discoveries into a broader framework of RNA-based gene regulation had its roots in this shared institutional environment at Harvard.

Career

Early Research and University of Massachusetts

Following the completion of his doctoral studies at Harvard, Mello pursued postdoctoral research before joining the faculty at the University of Massachusetts Medical School (now the University of Massachusetts Chan Medical School) in Worcester, Massachusetts. At UMass, Mello established a research laboratory focused on studying gene regulation and developmental biology using the nematode worm Caenorhabditis elegans (C. elegans) as a model organism. C. elegans has been a valuable tool for molecular biologists because of its simple anatomy, well-characterized genome, and tractability for genetic experiments. The organism's transparency allows researchers to observe individual cells directly under the microscope, and its invariant cell lineage — every adult worm of the same sex has exactly the same number of somatic cells, produced by an identical sequence of cell divisions — makes it an especially powerful system for studying developmental genetics.

Mello's early work at UMass explored the mechanisms of gene expression during development, seeking to understand how cells in a developing organism interpret genetic instructions to differentiate into specialized cell types. His laboratory developed innovative techniques for manipulating gene expression in C. elegans, including methods for introducing foreign genetic material into the worm to study the effects on development and cellular function. This technical expertise in germline transformation and microinjection methods proved directly applicable when he and Fire began designing experiments to probe the mechanism of gene silencing by RNA.

Discovery of RNA Interference

The discovery that would define Mello's career and earn him the Nobel Prize began in the mid-1990s through a collaboration with Andrew Z. Fire, who was then at the Carnegie Institution of Washington. The two researchers had been investigating the puzzling results obtained by scientists who tried to silence genes in C. elegans using antisense RNA — single-stranded RNA molecules complementary to the messenger RNA (mRNA) of a target gene. While antisense RNA could sometimes reduce gene expression, the results were inconsistent and the mechanism was poorly understood. In particular, researchers had noted that preparations of so-called antisense RNA frequently contained trace amounts of double-stranded RNA due to the tendency of complementary single-stranded molecules to anneal, and it remained unclear whether this contamination might be responsible for at least some of the observed gene-silencing effects.

Mello and Fire, along with their colleagues, conducted a series of carefully designed experiments to determine whether double-stranded RNA (dsRNA) — consisting of both sense and antisense strands paired together — might be more effective at silencing genes than either strand alone. In their landmark 1998 paper published in Nature, titled "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans," they reported a remarkable finding: when double-stranded RNA molecules corresponding to specific genes were injected into C. elegans, the expression of those genes was silenced with extraordinary potency and specificity.

The results were striking in several respects. First, double-stranded RNA was far more effective at gene silencing than either the sense or antisense strands individually, suggesting that the two strands together triggered a specific biological pathway. Second, only a small amount of dsRNA was needed to produce a potent silencing effect, implying that the response was catalytic or amplified by the cell. Third, the silencing was highly specific: only genes matching the sequence of the introduced dsRNA were affected, while other genes continued to function normally. Fourth, and perhaps most remarkably, the gene-silencing effect could spread from cell to cell within the organism and could even be transmitted to offspring. This systemic and heritable quality of the response suggested that RNAi was not merely a localized biochemical event but rather a coordinated, organism-wide surveillance mechanism.

Mello and Fire coined the term "RNA interference" (RNAi) to describe this phenomenon. Their discovery revealed a previously unknown mechanism of gene regulation that operates in cells from a wide range of organisms, from plants and fungi to insects and mammals. Subsequent research by laboratories around the world demonstrated that RNAi is an ancient and conserved biological defense mechanism, likely evolved to protect organisms against viruses and mobile genetic elements (transposons) that use double-stranded RNA intermediates during their replication. The evolutionary conservation of the RNAi pathway across such a wide range of species underscored its fundamental importance and suggested that it had arisen very early in the history of eukaryotic life.

The discovery also illuminated the broader role of small RNA molecules in gene regulation. Researchers subsequently found that cells produce their own small RNA molecules — known as small interfering RNAs (siRNAs) and microRNAs (miRNAs) — that use the RNAi machinery to regulate gene expression as part of normal development and cellular function. This connection to endogenous gene regulation greatly expanded the significance of Mello and Fire's initial discovery. The RNAi discovery thus served as a conceptual bridge, linking earlier observations about post-transcriptional gene silencing in plants — a phenomenon known as co-suppression — to a unified mechanistic framework that could be studied and applied across the tree of life.

Subsequent Research

Following the 1998 publication, Mello continued to investigate the molecular mechanisms underlying RNA interference and related small RNA pathways. His laboratory at UMass made important contributions to understanding how the RNAi machinery processes double-stranded RNA, how small RNA molecules are loaded onto Argonaute proteins to form silencing complexes, and how these complexes find and silence their target genes. The Argonaute protein family, which lies at the mechanistic heart of the RNAi pathway, became a major focus of the Mello laboratory's efforts to dissect the biochemistry of gene silencing at the molecular level.

Mello's continued research has explored the role of Argonaute small-RNA pathways in the germline of C. elegans, where these pathways play a critical role in silencing self-replicating genetic elements such as transposons. A 2021 study from his laboratory investigated how cues from mRNA splicing help distinguish the organism's own genes from foreign genetic elements, preventing default Argonaute-mediated silencing of the organism's own transcripts. This line of inquiry addressed a fundamental question in cell biology: how does the RNAi surveillance machinery, which must be vigilant enough to detect and suppress foreign genetic invaders, avoid erroneously silencing the cell's own essential transcripts? The finding that intron splicing signals serve as molecular identity tags for endogenous mRNAs provided a compelling answer to this question and added a new dimension to understanding how cells balance genomic defense against normal gene expression.

A 2023 study from his group examined how the nuclear Argonaute protein HRDE-1 directs target gene re-localization and shuttles to specialized structures called nuage to promote small RNA-mediated inherited gene silencing across generations. Nuage — also known as germ granules or P granules in C. elegans — are membraneless organelles found in the cytoplasm of germline cells that are thought to function as sites of RNA surveillance and small RNA biogenesis. The finding that HRDE-1 moves between the nucleus and these cytoplasmic compartments suggested a dynamic and spatially regulated mechanism for transmitting epigenetic gene-silencing information across generations.

These studies have contributed to a deeper understanding of epigenetic inheritance — how information beyond the DNA sequence can be transmitted from one generation to the next — and the mechanisms by which cells distinguish self from non-self at the level of RNA. More broadly, this body of work has positioned the Mello laboratory at the forefront of research into transgenerational epigenetic inheritance, a field with implications for understanding how environmental exposures and developmental experiences might influence the biology of subsequent generations.

Howard Hughes Medical Institute

In 2000, Mello was appointed as an investigator of the Howard Hughes Medical Institute (HHMI), one of the most prestigious positions in American biomedical research. HHMI investigators receive long-term research support that allows them to pursue ambitious and high-risk scientific questions without the constraints of traditional short-term grant cycles. This model of sustained, flexible funding is particularly well suited to the kind of curiosity-driven basic research that characterized Mello's work on RNAi mechanisms and small RNA biology. Mello's appointment reflected the recognition by the broader scientific community of the transformative potential of his work on RNA interference even before the Nobel Prize was awarded. His continued tenure as an HHMI investigator through subsequent decades has supported the expansion of his laboratory's research into epigenetic inheritance and the molecular architecture of the germline surveillance machinery.

RNA Therapeutics Institute

Mello has played a central role in the development of the RNA Therapeutics Institute (RTI) at UMass Chan Medical School, where he serves as a founding co-director alongside Phil Zamore, Victor Ambros, and Melissa Moore. The RTI was established to translate fundamental discoveries in RNA biology — including RNAi — into clinical therapies. The institute brings together researchers working on various aspects of RNA science, from basic mechanisms of gene regulation to the development of RNA-based drugs. Its formation reflected a broader strategic commitment by UMass Chan Medical School to capitalize on the extraordinary concentration of RNA biology expertise assembled on its campus, much of it traceable to the foundational discoveries of Mello, Ambros, Zamore, and Moore.

The translational potential of Mello's discovery became a reality when the first RNAi-based drug began approaching clinical approval. In 2017, media reports noted that the first drug based on the RNAi mechanism was nearing the market, representing the culmination of nearly two decades of research and development following the original 1998 discovery. The drug, patisiran (marketed as Onpattro), was approved by the U.S. Food and Drug Administration in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis, becoming the first FDA-approved therapy based on the RNAi mechanism. This milestone validated the therapeutic promise of Mello and Fire's foundational discovery and opened the door for additional RNAi-based therapeutics. Since the approval of patisiran, several other RNAi-based drugs have received regulatory approval or entered late-stage clinical development, targeting conditions including high LDL cholesterol, hepatitis B, and rare metabolic disorders, further demonstrating the breadth of therapeutic applications enabled by the mechanism that Mello and Fire first characterized in C. elegans.

Celebration of Collaborator Victor Ambros's Nobel Prize

When the Nobel Prize in Physiology or Medicine for 2024 was awarded jointly to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation, Mello was among the most vocal celebrants at UMass Chan Medical School. Members of the Ambros laboratory and other colleagues gathered to mark the occasion, with Mello joining the celebrations in recognition of his former doctoral mentor and long-standing colleague. The moment was notable for the rare distinction it conferred upon UMass Chan Medical School as an institution that had housed two Nobel laureates in Physiology or Medicine on its faculty simultaneously, with Mello's 2006 prize and Ambros's 2024 prize together representing the school's central role in the RNA biology revolution of the late twentieth and early twenty-first centuries. The two prizes, separated by eighteen years, were also connected by a deeper scientific logic: both the RNAi pathway that Mello and Fire discovered and the microRNA pathway that Ambros and Ruvkun characterized rely on overlapping molecular machinery, and the convergence of these two lines of research has been central to the emergence of RNA biology as one of the most active and consequential fields in modern biomedical science.

Advocacy for Research Funding

In addition to his laboratory research, Mello has been an active advocate for public investment in scientific research. In February 2026, Mello joined fellow Nobel laureates and UMass Chan Medical School leaders in urging Massachusetts state lawmakers to pass the DRIVE legislation, a package of measures designed to protect research funding and jobs in Massachusetts amid federal budget cuts that threatened to reduce support for biomedical research. Mello and his colleagues argued that sustained investment in research was essential for maintaining the state's position as a leader in biomedical innovation and for protecting the scientific workforce that drives new discoveries and therapies. The advocacy effort underscored the degree to which Mello has viewed his public role as extending beyond the laboratory, and reflected a broader concern among basic scientists about the long-term consequences of reduced federal support for fundamental research. His willingness to engage publicly on issues of science policy has made him a visible spokesperson for the biomedical research community in Massachusetts.

Personal Life

Craig Mello lives in the Worcester, Massachusetts area, where he has been based throughout his career at UMass Chan Medical School. Details of his personal life remain largely private, consistent with his preference for letting his scientific work speak for itself. In his Nobel biographical essay, Mello has spoken about the importance of family and the support of his loved ones in enabling his scientific career. He has also reflected publicly on the experience of receiving the Nobel Prize, describing the recognition as humbling and as an acknowledgment not only of his own work but of the broader scientific community whose collective efforts made the significance of RNAi apparent. Mello has noted in interviews and public statements that much of the most important science is done collaboratively and that the singular attribution implied by prize culture can obscure the communal nature of scientific discovery.

Recognition

Mello has received numerous awards and honors for his contributions to molecular biology and the discovery of RNA interference.

The most prominent of these is the Nobel Prize in Physiology or Medicine, which he received jointly with Andrew Z. Fire in 2006. The Nobel Assembly at Karolinska Institutet cited their "discovery of RNA interference — gene silencing by double-stranded RNA" as the basis for the award. The prize recognized not only the elegance and rigor of their original experiments but also the rapid and far-reaching impact of their discovery on biology and medicine. At the time of the award, the Nobel Committee noted that RNA interference had already become an indispensable research tool for biologists studying gene function in organisms across the tree of life. The speed with which the Nobel Prize followed the original publication — just eight years after the 1998 paper appeared in Nature — was itself a reflection of the unusually rapid and transformative impact of the discovery on the practice of biology.

Prior to the Nobel Prize, Mello and Fire received the Wiley Prize in 2003, awarded by the Wiley Foundation for contributions to biomedical science. In 2005, Mello received the Canada Gairdner International Award (also known as the Gairdner Foundation International Award), one of the most prestigious prizes in biomedical research and often considered a precursor to the Nobel Prize. The Gairdner Award recognized the broad significance of the RNAi discovery for both basic biology and its emerging medical applications, and it was one of several major prizes that Mello and Fire received in the years immediately preceding the Nobel award, as the scientific community converged on a consensus about the magnitude of their contribution.

Mello has also been honored with the NAS Award in Molecular Biology from the National Academy of Sciences and the Massry Prize from the Meira and Shaul G. Massry Foundation.

In addition, Mello received the Golden Plate Award from the Academy of Achievement.

Mello's work has also been recognized through patents. A patent (U.S. Patent 6,506,559) was granted for aspects of the technology related to genetic inhibition by double-stranded RNA, reflecting the applied significance of the RNAi discovery. The patent became commercially significant as the biotechnology and pharmaceutical industries moved to develop RNAi-based therapeutic and research tools, and it reflected the dual nature of foundational basic science discoveries as both intellectual achievements and technological innovations with practical value.

Legacy

The discovery of RNA interference by Craig Mello and Andrew Fire represents one of the most significant advances in molecular biology in the late twentieth century. Before their 1998 publication, the role of double-stranded RNA in gene regulation was essentially unknown. Their finding revealed an entirely new layer of gene regulation that operates in virtually all eukaryotic organisms, from single-celled fungi to humans.

RNAi rapidly became one of the most widely used tools in biological research. By introducing synthetic small interfering RNAs into cells, researchers can selectively silence any gene of interest to study its function — an approach that has been applied to thousands of genes across many species. This "reverse genetics" approach accelerated the pace of gene function discovery and made it possible to systematically investigate the roles of individual genes in health and disease. Genome-wide RNAi screens, in which thousands of genes are systematically silenced one by one to identify those involved in a particular biological process, became a standard methodology in the decade following the 1998 publication, enabling discoveries in areas ranging from cancer biology to infectious disease.

Beyond its utility as a research tool, RNAi has had a transformative impact on medicine. The development of RNAi-based therapeutics, beginning with the approval of patisiran in 2018, demonstrated that the mechanism Mello and Fire discovered could be harnessed to treat human disease by silencing disease-causing genes. Multiple additional RNAi-based drugs have since entered clinical development for conditions ranging from cardiovascular disease to rare genetic disorders, establishing RNAi therapeutics as a growing class of medicines alongside traditional small-molecule drugs and biologic therapies. The field of RNA therapeutics more broadly — which encompasses not only RNAi-based drugs but also antisense oligonucleotides and mRNA therapeutics — owes a significant conceptual and practical debt to Mello and Fire's demonstration that RNA molecules could be deployed with precision and potency to alter gene expression in living organisms.

The institutional legacy of Mello's work is also evident at UMass Chan Medical School, where the RNA Therapeutics Institute that he co-founded has become a major center for RNA science and drug development. The presence of multiple Nobel laureates on the UMass Chan faculty — including Mello and his former mentor Victor Ambros, who won the Nobel Prize in 2024 — has helped establish the institution as one of the foremost centers for RNA biology in the world. The intertwined scientific histories of Mello and Ambros, from their shared years at Harvard through their parallel careers at UMass Chan and their successive Nobel Prizes for discoveries in RNA-mediated gene regulation, represent an unusual instance of mentor and student both achieving the highest recognition in their field for related but distinct contributions.

Mello's discovery also contributed to the broader recognition that RNA molecules play far more diverse and important roles in cells than had previously been appreciated. Before the RNAi discovery, RNA was primarily viewed as a passive intermediary between DNA and protein. The finding that small RNA molecules can actively regulate gene expression helped catalyze a wider revolution in RNA biology, leading to discoveries of numerous other classes of regulatory RNA molecules and their roles in development, immunity, and disease. Long non-coding RNAs, circular RNAs, PIWI-interacting RNAs, and other classes of functional RNA molecules have all emerged as important subjects of investigation in the decades since the RNAi discovery, and the conceptual framework established by Mello and Fire's work — that RNA is an active participant in gene regulation rather than merely a passive messenger — has underpinned much of this subsequent research.